Metastatic castration-resistant prostate cancer: Changing landscape with cabazitaxel

Anti-Cancer Drugs

Volumn 25, Issue 3, 2014, Pages 237-243

  Fernández, Ovidio ^a   Afonso, Javier ^b   Vázquez, Sergio ^e   Campos, Begoña ^e   Lázaro, Matín ^f   León, Luis ^c   Antón Aparicio, Luis M ^d  

^a Ourense Hospital Complex   (Spain)

^b Universidad de La Coruña   (Spain)

^c Santiago University Hospital   (Spain)

^d University Hospital Complex of A Coruña   (Spain)

^e University Hospital Lucus Augusti   (Spain)

^f University Hospital Complex of Vigo   (Spain)

Author keywords

Cabazitaxel; Metastatic castration resistant prostate cancer; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS;

EID: 84895077087     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000045     Document Type: Review

References (30)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 756-764.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer leukemia group B 9182 study. J Clin Oncol 1999; 17: 506-513.
3. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
5. Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 2012; 13: 1676-1686.
6. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
7. Aller AW. In vitro activity of TXD258 in chemotherapeutic resistant tumour xenografts [abstract]. Proc Am Assoc Cancer Res 2000; 41:1923.
8. Bissery MC, Bouchard H, Riou JF. Preclinical evaluation of TXD258, a new taxoid [abstract]. Proc Am Assoc Cancer Res 2000; 41:1364.
9. Sanofi-Aventis. XRP6258 investigator's brochure. Antony, France: Sanofi-Aventis; 2000.
10. Sanofi-Aventis. Jevtana (cabazitaxel injection approved by U.S. FDA after priority review), 2010.
11. Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, et al. Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer 2013; 49: 25-34.
12. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 2009; 15: 723-730.
13. Pivot X, Koralewsky P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h IV infusion every three weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19: 1547-1552.
14. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 2011; 7: 497-506.
15. Bavbek SE, Malik Z, di Lorenzo G, Scholz HJ, van Oort IM, Ng S, et al. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: interim results [abstract]. J Clin Oncol 2012; 30 (Suppl 5):172.
16. Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279) [abstract]. J Clin Oncol 2012; 30 (Suppl 5):44.
17. Bracarda S, di Lorenzo G, Gasparro D, Marchetti P, Boccardo F, Martoni A, et al. Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy [abstract]. J Clin Oncol 2012; 30 (Suppl):e15185.
18. De Velasco G, Anton L, Esteban E, Pérez Q, Sánchez- Hernández A, Pérez Valderrama B, et al. Cabazitaxel in patients with advanced CRPC after docetaxel failure: results of expanded program access (EAP) in Spain: safety and efficacy [abstract]. J Clin Oncol 2012; 30 (Suppl):e15149.
19. Di Lorenzo G, D'Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 2013; 24: 84-89.
20. Massard C, Pezaro C, Bobilev D, Omlin AG, Bianchini D, Lorente Estelles D, et al. A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: preliminary results [abstract]. J Clin Oncol 2013; 31 (Suppl):5049.
21. Fumoleau P. Phase I and pharmacokinetics studies of RRPR116258A given as a weekly 1-h infusion at day 1, day 8, day 15, and day 22 every 5 weeks in patients with advanced solid tumours. AACR-NCI-EORTC Int Conf Mol Target Cancer Ther. Miami Beach, 29 October 2001-2 November 2001; 2001, A282.
22. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
23. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
24. Mukherji D, Pezaro CJ, Bianchini D, Zivi A, de Bono JS. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel [abstract]. J Clin Oncol 2012; 30 (Suppl 5):17.
25. Chi KN, Scher HI, Molina A, Logothetis CJ, Jones RJ, Staffurth J, et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol 2012; 30 (Suppl 5):15.
26. Azria D, Massard C, Tosi D, HouédéN, Joly F, Gravis G, et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response [abstract]. J Clin Oncol 2012; 30 (Suppl 5):149.
27. Oudard S, de Bono JS, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Impact of cabazitaxel plus prednisone on overall survival at years and in patients with aggressive disease: post-hoc analyses of TROPIC trial. 933P [abstract]. ESMO 2012;1857.
28. Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P Puglia L. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol 2013; 9: 889-897.
29. Loriot Y, Massard C, Albiges L, Di Palma M, Blanchard P, Bossi A, et al. Personalizing treatment in patients with CRPC: a study of predictive factors for secondary endocrine therapies activity [abstract]. J Clin Oncol 2012; 30 (Suppl 5):abstract 213.
30. Ryan C, Li J, Kheoh T, Scher HI, Molina A. Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 phase III randomized trial. AACR 2012; 72 (8, Suppl):LB-434.